Institutional members access full text with Ovid®

Share this article on:

Rituximab in Lymphomatoid Granulomatosis

Hernández-Marqués, Carmen MD; Lassaletta, Alvaro MD; Torrelo, Antonio MD; López-Pino, Miguel Ángel MD; Álvarez-Coca, Javier MD; De Prada, Inmaculada MD; Hernández-Martín, Ángela MD; Madero, Luis MD

Journal of Pediatric Hematology/Oncology: March 2014 - Volume 36 - Issue 2 - p e69–e74
doi: 10.1097/MPH.0b013e31827e63a6
Online Articles: Clinical and Laboratory Observations

Background: Lymphomatoid granulomatosis (LG) is an Epstein-Barr virus–associated, multisystemic disease that combines a granulomatous inflammatory process with lymphoproliferative potential. It is a rare disorder with a variable clinical presentation ranging from an indolent process to an aggressive B-cell lymphoma. Outcome is unpredictable, and a standard treatment has not yet been established. Cases treated with rituximab, an anti-CD20 monoclonal antibody, have been reported with variable results.

Observation: We report on 2 children with LG treated with rituximab and review the literature. The first patient had good response but the second did not.

Conclusions: Rituximab is a treatment option for LG.

Departments of *Pediatric Hematology-Oncology




Pathology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain

The authors declare no conflict of interest.

Reprints: Alvaro Lassaletta, MD, Department of Paediatric Haematology-Oncology, Hospital Infantil Universitario Niño Jesús, Avenida Menéndez Pelayo 65, Madrid 28009, Spain (e-mail:

Received June 14, 2012

Accepted November 15, 2012

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.